LPCN
What one share of Lipocine holds
Pharmaceutical Preparations
Lipocine’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.23 |
|---|---|
| Profit | −$1.75 |
| Cash and investments | $0.60 |
| Book value | $2.64 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $1.73 | $0.85 | $0.00 | −$0.72 | — | $1.19 |
| 2013 | $0.00 | −$1.44 | $0.00 | −$1.17 | — | $3.54 |
| 2014 | — | −$1.60 | $0.00 | −$1.36 | — | $2.06 |
| 2015 | — | −$1.11 | $0.00 | −$0.93 | — | $2.30 |
| 2016 | $0.00 | −$1.04 | $0.00 | −$1.00 | — | $1.41 |
| 2017 | $0.00 | −$1.05 | $0.00 | −$0.83 | — | $0.89 |
| 2018 | $0.02 | −$0.55 | $0.00 | −$0.57 | — | $0.43 |
| 2019 | $0.01 | −$0.50 | — | −$0.45 | — | $0.17 |
| 2020 | $0.00 | −$0.38 | — | −$0.27 | — | $0.22 |
| 2021 | $0.18 | −$0.01 | $0.00 | −$0.05 | — | $0.52 |
| 2022 | $0.10 | −$2.15 | $0.03 | −$2.30 | — | $6.81 |
| 2023 | −$0.54 | −$3.14 | $0.00 | −$2.25 | — | $3.83 |
| 2024 | $2.07 | −$0.00 | $0.02 | −$0.24 | — | $3.93 |
| 2025 | $0.35 | −$1.69 | — | −$1.71 | — | $2.35 |